AUXL 32.66 Auxilium Pharmaceuticals $AUXL Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 5, 2014 at 10:22 PM

AUXL 32.66 Auxilium Pharmaceuticals $AUXL Hit a 52 week high of 33.13 Closing the day 11/05/14 at 32.66 +0.08 +0.25% With a day low of 32.26 and a total volume of 1,644,293.

AUXL Recent Posts: http://investorshangout.com/Auxilium-Pharmace...UXL-53427/

AUXL Auxilium Pharmaceuticals Recent Headline News

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 102.77 (-1.06), ENDP: 68.70 (+0.03), AUXL: 32.66 (+0.08), SHPG: 198.61 (+2.99), DNDN: 0.93 (-0.05), SNSS: 1.70 (+0.02), ABBV: 62.54 (-0.12), SNY: 45.70 (+0.21), MNKD: 5.67 (-0.25), XOMA: 4.00 (-0.18)

60.1% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Nov 03, 10:57AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 60.09% as of today's recent price of $32.33.
AUXL: 32.66 (+0.08)

Flamel Technologies (FLML) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:38AM CST
Flamel Technologies (FLML) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down nearly 15% in the past one-month time frame.
FLML: 11.76 (-0.27), AUXL: 32.66 (+0.08), IG: 9.55 (-0.40), BIOD: 1.50 (+0.01)

Auxilium Pharmaceuticals, Inc. to Present XIAFLEX and STENDRA Data at SMSNA Scientific Meeting
PR Newswire - Mon Nov 03, 5:00AM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease (PD) and STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) will be presented at the upcoming 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) being held in Miami from November 20-23, 2014.
AUXL: 32.66 (+0.08)

Pacira Down on Wider than Expected Q3 Loss, Sales Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:00PM CDT
Pacira Pharmaceuticals' (PCRX) third-quarter 2014 loss of 5 cents per share was wider than the Zacks Consensus Estimate of a loss of a penny but much narrower than the year-ago loss of 41 cents per share.
LCI: 53.15 (-3.10), VRX: 131.91 (-1.70), AUXL: 32.66 (+0.08), PCRX: 87.71 (-2.27)

The Zacks Analyst Blog Highlights:Endo International, Auxilium Pharmaceuticals, Infinity Pharmaceuticals and Karyopharm Therapeutics
PR Newswire - Thu Oct 30, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Endo International (Nasdaq:ENDP-Free Report), Auxilium Pharmaceuticals Inc. (Nasdaq:AUXL-Free Report), Infinity Pharmaceuticals, Inc. (Nasdaq:INFI-Free Report) and Karyopharm Therapeutics, Inc. (Nasdaq:KPTI-Free Report).
AUXL: 32.66 (+0.08), INFI: 12.29 (-0.49)

QLT (QLTI) Reports Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:00AM CDT
QLT Inc. (QLTI) reported a third-quarter 2014 loss of 10 cents.
QLTI: 3.95 (-0.03), VRX: 131.91 (-1.70), AUXL: 32.66 (+0.08), BMY: 57.82 (-0.02)

Auxilium reports 3Q loss
Automated Insights - Thu Oct 30, 6:07AM CDT
CHESTERBROOK, Pa. (AP) _ Auxilium Pharmaceuticals Inc. (AUXL) on Thursday reported a third-quarter loss of $32.7 million.
AUXL: 32.66 (+0.08)

Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.
AUXL: 32.66 (+0.08)

54.9% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Oct 27, 9:37AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 54.94% as of today's recent price of $31.29.
AUXL: 32.66 (+0.08)

Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 68.70 (+0.03), PRGO: 158.50 (-1.35), AUXL: 32.66 (+0.08), DEPO: 14.92 (-0.40), AMPE: 3.73 (-0.07)

Omeros Falls as Enrollment for OMS824 Study is Suspended - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 3:10PM CDT
Omeros Corporation (OMER) suffered a pipeline setback with the company announcing the suspension of enrollment in a phase II study evaluating OMS824.
MDVN: 102.77 (-1.06), AUXL: 32.66 (+0.08), LGND: 55.29 (-0.98), OMER: 17.24 (+0.12)

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients
PR Newswire - Mon Oct 20, 4:30PM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics Application (sBLA) for XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same hand during a single treatment visit.
AUXL: 32.66 (+0.08)

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Auxilium Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Sun Oct 19, 5:26PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Auxilium Pharmaceuticals, Inc. ("Auxilium" or the "Company"

(Nasdaq: AUXL) relating to the proposed buyout of the Company by Endo International plc ("Endo"

.
AUXL: 32.66 (+0.08)

AUXILIUM PHARMACEUTICALS INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. Over the Proposed Sale of the Company to Endo International PLC -AUXL
PR Newswire - Fri Oct 17, 5:30PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or the "Company"

(Nasdaq: AUXL) for potential breaches of fiduciary duties in connection with the sale of the Company to Endo International Plc ("Endo"

for approximately $2.6 billion. The Company's stockholders may elect to receive a combination of $16.625 in cash plus 0.2440 Endo ordinary shares, $33.25 in cash, or 0.4880 Endo ordinary shares for each share of Auxilium stock they own.
AUXL: 32.66 (+0.08)

Tekmira Presents Data on Hepatitis B Candidate TKM-HBV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 4:30PM CDT
Tekmira Pharmaceuticals Corporation (TKMR) presented encouraging preclinical data on its hepatitis B infection candidate, TKM-HBV.
MDVN: 102.77 (-1.06), AUXL: 32.66 (+0.08), LGND: 55.29 (-0.98), TKMR: 15.12 (-1.13)

Lifshitz & Miller Law Firm Announces Investigation of Apco Oil & Gas International Inc., Arrowhead Research Corporation, Auxilium Pharmaceuticals, Inc., EveryWare Global, Inc., and Gentiva Health Services, Inc.
PR Newswire - Wed Oct 15, 4:23PM CDT
Apco Oil & Gas International Inc.
APAGF: 14.25 (+0.29), ARWR: 6.19 (-0.22), AUXL: 32.66 (+0.08), EVRY: 1.06 (-0.05), GTIV: 19.55 (+0.21)

Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 12:59PM CDT
Will Gilead's new HCV combo treatment pick up share like Sovaldi and bring in multi-billion dollar sales for the company?
VRTX: 111.59 (-2.51), ALNY: 88.01 (-1.98), GILD: 106.05 (-3.67), SRPT: 15.17 (-1.21), AUXL: 32.66 (+0.08), AMGN: 158.94 (-1.47), ABBV: 62.54 (-0.12)

Auxilium Pharmaceuticals Inc. (AUXL) Stock Research Links

AUXL Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Business Leaders Push for Justice Reform Policy

Business stepping up to bat for justice reform? Yeah, that’s what's shaking over in Washington, D.C. this Constitution Day. We're seeing a gathering of senior business execs, policymakers, and public safety advocates, intent on driving judicial reform in the U.S. Usually, the suits in these rooms talk about profit margins and quarterly results, but this time they're...

Baystate Noble Plans Major ED Expansion for Future Needs

A Trusted Name in Healthcare Steps Up When a healthcare player like Baystate Health decides to jump into the deep end with an expansion project, you know they're not just doodling on napkins. With a legacy stretching back to 1883, Baystate Health, anchored deeply in western New England, isn't just expanding for fun—it's a move to cement its position as a crucial...

Jeen's Real-Time AI Cost Management Unveiled

Unmasking the Ghosts in AI Expenses Enterprises are thrashing around in the digital ocean of AI, yet many still can't see what's draining their coffers. It's not just the savant data scientists racking up the charges; it's every automated agent chipping away at resources—unnoticed until the bill finally lands. That's where Jeen is stepping in, flipping the script on...

Jamba's Cloud Whip: A Bold Blend in Beverage Scene

An Unexpected Shake-Up in the Beverage Game Folks, brace yourselves because Jamba's making some bold moves. I remember a time when a smoothie was just a smoothie, but now, they're stacking up a new deck with this fancy thing they're calling 'Cloud Whip'. It's basically a way to slap some extra protein onto your drink, with 10 grams coming at you like a freight train...

SCO at 25: China's Strategic Push for Regional Growth

There's a new beat coming out of Central Asia, and it's resonating all the way from China's boardrooms to the barren landscapes of the Gobi Desert. With the Shanghai Cooperation Organization (SCO) celebrating its 25th anniversary, we're witnessing a pivot from a security-centric setup to a full-blown economic collaboration machine. The Landscape of SCO's Evolution Look,...

Innventure Faces Class Action Over Alleged Deception

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Kevin Hart & Pragmatic Play Revamp Live Casino Scene

Where Comedy Meets Chances You've got Kevin Hart, larger than life, and then you've got Pragmatic Play—a key player in iGaming. Put them together and you've got an event that might turn the usual casino lights into a full-blown spotlight. They're not just throwing dice, they're shaking up the market with potential way beyond what meets the eye. Okay, so here's the...

Elbphilharmonie Hamburg: 10th Anniversary Marks Milestone

Elbphilharmonie's Impact on Hamburg's Cultural Landscape Here we are, staring down the first decade of the Elbphilharmonie, and boy, if that isn't a testament to sticking your neck out for culture, I don't know what is. Opened back on January 11, 2017, this concert hall started as just another controversial project, folks wagging tongues about costs and ambition. But...

RealityMine Appoints CPO Amidst Strong Growth Momentum

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Comcast Unveils Game-Changing Next-Gen Video AI

Comcast Technology Solutions Takes a Big Swing Well, Comcast Technology Solutions (CTS) is stepping up to the plate with an offering that just might knock it out of the park for broadcasters and content creators. They're rolling out an ambitious suite of AI-powered video workflow tools that could potentially redefine how operators handle their media libraries. The buzz is...